LungLife AI, INC Total Voting Rights (2078G)
November 30 2022 - 2:00AM
UK Regulatory
TIDMLLAI
RNS Number : 2078G
LungLife AI, INC
30 November 2022
LungLife AI, Inc.
(the "Company" or "LungLife")
Total Voting Rights
The Company's total issued share capital consists of 25,485,982
Ordinary Shares of US $0.0001 each ("Ordinary Shares") with one
voting right per Ordinary Share. There are no Ordinary Shares held
in treasury. The total number of voting rights in the Company is
therefore 25,485,982. This number may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in the Company under the FCA's Disclosure Guidance
and Transparency Rules.
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com
Paul Pagano, CEO Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser Tel: +44 (0)20 7597 5970
& Broker)
Daniel Adams / Virginia Bull / Cameron
MacRitchie
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Paul McManus / Alice Woodings / Phillip Mob: 07980 541 893 / 07407 804 654 /
Marriage 07867 984 082
About LungLife AI
LungLife AI is a developer of clinical diagnostic solutions
designed to make a significant impact in the early detection of
lung cancer, the deadliest cancer globally. Using a minimally
invasive blood draw, the Company's LungLB(R) test is designed to
deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit
www.lunglifeai.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRDFLFFLFLBFBZ
(END) Dow Jones Newswires
November 30, 2022 02:00 ET (07:00 GMT)
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From May 2024 to Jun 2024
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From Jun 2023 to Jun 2024